Home › Research › Prevention and risk
Association of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease
Dean DC, Hurley SA, Kecskemeti SR, O'Grady JP, Canda C, Davenport-Sis NJ, Carlsson CM, Zetterberg H et al.. JAMA neurology, 2017-01-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Results The mean (SD) age for the 19 male participants and 52 female participants in the study was 61.6 (6.4) years. Quantitative relaxometry measures were negatively associated with levels of CSF biomarkers across brain white matter and in areas preferentially affected in AD. Furthermore, significant age-by-biomarker interactions were observed between myelin water fraction and phosphorylated tau 181/β-amyloid 42, suggesting that phosphorylated tau 181/β-amyloid 42 levels modulate age-related changes in myelin water fraction. Conclusions and relevance These findings suggest amyloid pathologies significantly influence white matter and that these abnormalities may signify an early feature of the disease process.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study. In this small study of 71 participants, amyloid pathology was associated with changes in myelin in the brain's white matter, suggesting these abnormalities may be an early feature of Alzheimer's disease. This was an observational study and does not show that treating myelin changes would prevent or cure the disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Dean, D. C., Hurley, S. A., Kecskemeti, SR., O'Grady, J. P., Canda, C., Davenport-Sis, N. J., et al. (2017). Association of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease. JAMA neurology. https://doi.org/10.1001/jamaneurol.2016.3232
Vancouver
Dean DC, Hurley SA, Kecskemeti SR, O'Grady JP, Canda C, Davenport-Sis NJ, et al. Association of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease. JAMA neurology. 2017. doi:10.1001/jamaneurol.2016.3232. PMID: 27842175.
BibTeX
@article{dean2017-27842175,
author = {Dean, D. C. and Hurley, S. A. and Kecskemeti, SR. and O'Grady, J. P. and Canda, C. and Davenport-Sis, N. J. and Carlsson, C. M. and Zetterberg, H. and others},
title = {{Association of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease}},
journal = {JAMA neurology},
year = {2017},
doi = {10.1001/jamaneurol.2016.3232},
pmid = {27842175},
url = {https://doi.org/10.1001/jamaneurol.2016.3232}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results The mean (SD) age for the 19 male participants and 52 female participants in the study was 61.6 (6.4) years.
- Quantitative relaxometry measures were negatively associated with levels of CSF biomarkers across brain white matter and in areas preferentially affected in AD.
- Furthermore, significant age-by-biomarker interactions were observed between myelin water fraction and phosphorylated tau 181/β-amyloid 42, suggesting that phosphorylated tau 181/β-amyloid 42 levels modulate age-related changes in myelin water fraction.
- Conclusions and relevance These findings suggest amyloid pathologies significantly influence white matter and that these abnormalities may signify an early feature of the disease process.
Why it matters
In this small study of 71 participants, amyloid pathology was associated with changes in myelin in the brain's white matter, suggesting these abnormalities may be an early feature of Alzheimer's disease. This was an observational study and does not show that treating myelin changes would prevent or cure the disease.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Study designlongitudinal study
- Evidence strengthModerate
How this study scored 61/100
Published in a leading specialty journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA neurology) |
| Journal's citation record | 2 / 4 | JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2017 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 252 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 22.9 citations a year over 11 year(s) since 2017 |
| Impact for its field and year | 4 / 6 | Cited 11.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 12 other studies in this library |
| Still being cited | 3 / 4 | Cited 98 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Barbara B. Bendlin: h-index 64 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Oxford: institution h-index 2,205 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 27842175) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 61 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamaneurol.2016.3232
- PubMed: 27842175
- Original source →
- Free full text: PubMed Central →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.
Later studies that cite this one
12 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Prevention and risk from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.